期刊文献+

腹水中CD8^+ CD28^-T细胞表达水平对良恶性腹水的鉴别价值

The expression of CD8^+ CD28^- T cells in the benign and malignant diagnosis of ascites
下载PDF
导出
摘要 目的探讨良恶性腹水中CD8+CD28-T细胞表达水平及意义,以便为良恶性腹水的鉴别诊断提供新的思路和方法。方法采用流式细胞仪检测24例肝硬化性腹水、20例结核性腹水、28例恶性腹水中CD8+CD28-T细胞表达水平。结果恶性腹水组CD8+CD28-T细胞表达水平为(24.75±4.09)%,明显高于结核性腹水组(13.83±2.38)%及肝硬化性腹水组(16.15±1.49)%,后两组比较差异有统计学意义(P<0.05)。结论 CD8+CD28-T细胞表达水平在良恶性腹水中存在显著差异,可作为判定良恶性腹水的辅助诊断指标。 Objective To study the expression new technology for the early diagnosis of malignan of CD8 + CD28 - T cells in benign and malignant ascites and provide a t ascites. Methods Flow cytometry was used to test the levels of CD8 + CD28-T cells in hepatocirrhosis ascites (n = 24), tuberculous ascites (n = 20) and malignant ascites (n = 28). Results The percent of CD8 + CD28 - T cells in malignant ascites group (24.75 ± 4.09) % was higher than that in hep- atocirrhosis ascites group ( 16.15 ± 1.49) % and tuberculous ascites group ( 13.83 ± 2.38) % , there was statistically significant difference between hepatocirrhosis ascites and tuberculous ascites groups (P 〈 0.05). Conclusion CD8 + CD28-T ceils is significantly different between malignant ascites hepatocirrhosis ascites and tuberculous ascites, they could be used to distinguish malignant ascites from hepatocirrhosis and tuberculous.
出处 《胃肠病学和肝病学杂志》 CAS 2013年第10期1034-1036,共3页 Chinese Journal of Gastroenterology and Hepatology
关键词 结核性腹水 肝硬化性腹水 恶性腹水 CD8+CD28-T细胞 流式细胞仪 Tuberculous ascites Liver cirrhosis ascites Malignant ascites CD8 + CD28-T cells Flow cytometry
  • 相关文献

参考文献1

二级参考文献36

  • 1[1]Friedman JM,Halaas JL.Leptin and the regulation of body weight in mammals.Nature 1998; 395:763-770
  • 2[2]Friedman JM.Leptin,leptin receptors and the control of body weight.Eur J Med Res 1997; 2:7-13
  • 3[3]Tartaglia LA.The leptin receptor.J Biol Chem 1997; 272:6093-6096
  • 4[4]Kennedy A,Gettys TW,Watson P,Wallace P,Ganaway E,Pan Q,Garvey WT.The metabolic significance of leptin in humans:gender-based differences in relationship to adiposity,insulin sensitivity,and energy expenditure.J Clin Endocrinol Metab 1997; 82:1293-1300
  • 5[5]Considine RV,Sinha MK,Heiman ML,Kriauciunas A,Stephens TW,Nyce MR,Ohannesian JP,Marco CC,McKee LJ,Bauer TL.Serum immunoreactive-leptin concentrations in normal-weight and obese humans.N Engl J Med 1996; 334:292-295
  • 6[6]Van Gaal LF,Wauters MA,Mertens IL,Considine RV,De Leeuw IH.Clinical endocrinology of human leptin.Int J Obes Relat Metab Disord 1999; 23 Suppl 1:29-36
  • 7[7]Mantzoros CS.The role of leptin in human obesity and disease:a review of current evidence.Ann Intern Med 1999;130:671-680
  • 8[8]Greco AV,Mingrone G,Benedetti G,Capristo E,Tataranni PA,Gasbarrini G.Daily energy and substrate metabolism in patients with cirrhosis.Hepatology 1998; 27:346-350
  • 9[9]Shimizu H,Kakizaki S,Tsuchiya T,Nagamine T,Takagi H,Takayama H,Kobayashi I,Mori M.An increase of circulating leptin in patients with liver cirrhosis.Int J Obes Relat Metab Disord 1998; 22:1234-1238
  • 10[10]McCullough AJ,Bugianesi E,Marchesini G,Kalhan SC.Gender-dependent alterations in serum leptin in alcoholic cirrhosis.Gastroenterology 1998; 115:947-953

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部